Predictive Oncology Inc. (POAI)

Predictive Oncology Inc. (POAI) Healthcare & Pipeline Overview

Predictive Oncology Inc. leverages artificial intelligence to develop personalized cancer therapies, operating across four segments offering clinical testing, 3D disease models, protein stabilization, and fluid management solutions. With a focus on patient-centric drug discovery and advanced technologies, Predictive Oncology aims to improve cancer treatment outcomes.

What Is the Investment Thesis for POAI?

Predictive Oncology Inc. operates in the burgeoning field of personalized cancer therapies, leveraging AI and advanced technologies. The company's four segments offer diverse revenue streams and growth opportunities. However, with a market capitalization of $3.57M and a negative P/E ratio of -0.01, the company faces significant financial challenges. The negative profit margin of -11581.3% indicates substantial losses. Key value drivers include the expansion of AI-driven drug discovery services and the adoption of the STREAMWAY System in healthcare facilities. Upcoming catalysts include potential partnerships with pharmaceutical companies and positive clinical trial results from AI-driven therapies. Potential risks include intense competition, regulatory hurdles, and the need for additional capital to fund operations.

Based on FMP financials and quantitative analysis

POAI Key Highlights

• Market Cap of $3.57M indicates a micro-cap company with high growth potential but also higher risk.
• P/E Ratio of -0.01 reflects the company's current lack of profitability.
• Profit Margin of -11581.3% highlights significant operational challenges and high expenses.
• Gross Margin of 50.2% suggests a strong potential for profitability if operational costs are managed effectively.
• Beta of 1.35 indicates higher volatility compared to the market, reflecting the speculative nature of the stock.

Who Are POAI's Competitors?

POAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are POAI's Key Strengths?

• Proprietary AI platform for personalized cancer therapies.
• Diverse revenue streams across four business segments.
• Innovative STREAMWAY System for healthcare fluid management.
• Expertise in organ-specific disease modeling.

What Are POAI's Weaknesses?

• Negative profit margin and significant operational losses.
• Limited market capitalization and financial resources.
• Dependence on research and development for future growth.
• Intense competition in the healthcare and biotechnology industries.

What Could Drive POAI Stock Higher?

• Potential partnerships with pharmaceutical companies to co-develop personalized cancer therapies.
• Positive clinical trial results from AI-driven therapies.
• Expansion of AI-driven drug discovery services to increase revenue and market share.
• Increased adoption of the STREAMWAY System in hospitals and clinics to improve safety and efficiency.

What Are the Key Risks for POAI?

• Financial-distress signal — its Altman Z-Score of -29.11 sits in the distress zone (elevated bankruptcy risk).
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 6 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from larger and more established companies in the healthcare and biotechnology industries.
• Regulatory hurdles and compliance requirements for new therapies and medical devices.
• The need for additional capital to fund operations and research and development.
• Negative profit margin and significant operational losses, indicating financial instability.

What Are the Growth Opportunities for POAI?

• Expansion of AI-Driven Drug Discovery Services: Predictive Oncology can leverage its AI platform to expand its drug discovery services, targeting pharmaceutical companies seeking to accelerate drug development. The global AI in drug discovery market is projected to reach $2.01 billion by 2028, growing at a CAGR of 32.7% from 2021. This presents a significant opportunity for Predictive Oncology to increase its revenue and market share by offering AI-powered solutions that improve the efficiency and accuracy of drug discovery processes. Timeline: Ongoing.
• Increased Adoption of STREAMWAY System: The STREAMWAY System offers a unique solution for managing infectious fluids in healthcare settings, reducing staff exposure and improving safety. The global medical waste management market is expected to reach $16.6 billion by 2027, driven by increasing healthcare expenditure and stringent regulations. Predictive Oncology can capitalize on this trend by expanding the installation of the STREAMWAY System in hospitals and clinics, focusing on its safety and cost-effectiveness benefits. Timeline: Ongoing.
• Development of Organ-Specific Disease Models: The zPREDICTA segment's organ-specific disease models provide a valuable tool for testing anticancer agents and predicting drug responses. The market for preclinical oncology services is growing, driven by the increasing complexity of cancer research and the need for more accurate preclinical models. Predictive Oncology can expand its zPREDICTA services by developing new disease models and partnering with pharmaceutical companies to improve the success rate of clinical trials. Timeline: Ongoing.
• Strategic Partnerships with Pharmaceutical Companies: Predictive Oncology can form strategic partnerships with pharmaceutical companies to co-develop personalized cancer therapies and leverage its AI platform for drug discovery. These partnerships can provide access to funding, resources, and expertise, accelerating the development and commercialization of new therapies. The pharmaceutical industry is increasingly seeking collaborations with innovative technology companies to enhance their drug development pipelines. Timeline: Upcoming.
• Expansion of Clinical Testing Services: The Helomics segment offers clinical testing services, including tumor drug response testing and genomic profiling. The market for cancer diagnostics is growing, driven by the increasing incidence of cancer and the demand for personalized treatment approaches. Predictive Oncology can expand its Helomics services by offering new tests and expanding its geographic reach, focusing on providing accurate and timely information to guide treatment decisions. Timeline: Ongoing.

What Opportunities Does POAI Have?

• Expansion of AI-driven drug discovery services.
• Increased adoption of STREAMWAY System in healthcare facilities.
• Strategic partnerships with pharmaceutical companies.
• Growth in the cancer diagnostics and personalized medicine markets.

What Threats Does POAI Face?

• Regulatory hurdles and compliance requirements.
• Technological obsolescence and the need for continuous innovation.
• Competition from larger and more established companies.
• Economic downturns and reduced healthcare spending.

What Are POAI's Competitive Advantages?

• Proprietary AI platform for drug discovery and personalized cancer therapies.
• Unique organ-specific disease models for predicting drug responses.
• Patented STREAMWAY System for managing infectious fluids in healthcare settings.
• Expertise in protein stabilization and solubility analysis.

What Does POAI Do?

Predictive Oncology Inc., established in 2002 and formerly known as Precision Therapeutics Inc., is a knowledge-driven company committed to developing personalized cancer therapies using artificial intelligence (AI). Headquartered in Eagan, Minnesota, the company operates through four distinct segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides clinical testing services, including tumor drug response testing and genomic profiling. It also offers contract research services, employing active learning technology for drug discovery, clinical and translational research, clinical trials, and diagnostic development. The zPREDICTA segment focuses on developing organ-specific disease models, offering 3D reconstruction of human tissues to mimic disease states and drug responses for anticancer agent testing. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, an automated system for screening protein formulations for solubility and stability. This segment also offers protein stability analysis services, protein solubility kits, and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment features the STREAMWAY System, a wall-mounted, fully automated system designed to minimize staff exposure to infectious fluids in healthcare settings. Additionally, the company provides research and development services and media to support cancer cell growth outside the body, preserving their DNA/RNA and proteomic signatures. Predictive Oncology's integrated approach aims to enhance cancer treatment strategies through advanced technology and personalized solutions.

What Products and Services Does POAI Offer?

• Develop personalized cancer therapies using artificial intelligence.
• Offer clinical testing services, including tumor drug response testing and genomic profiling.
• Develop organ-specific disease models for testing anticancer agents.
• Provide services for protein stabilization and solubility analysis.
• Offer the STREAMWAY System for managing infectious fluids in healthcare settings.
• Provide research and development services for cancer cell growth and analysis.

How Does POAI Make Money?

• Generates revenue through clinical testing services offered by the Helomics segment.
• Earns revenue from the sale and installation of the STREAMWAY System through the Skyline segment.
• Derives income from contract research services and partnerships with pharmaceutical companies.
• Receives payments for protein stability analysis services and protein solubility kits through the Soluble segment.

What Industry Does POAI Operate In?

Predictive Oncology Inc. operates within the medical instruments and supplies industry, which is experiencing growth driven by technological advancements and increasing demand for personalized medicine. The market is competitive, with companies like AIM ImmunoTech Inc. (AIM), AMIX Biotech Holdings Inc. (AMIX), Bionano Genomics Inc. (BNGO), Cycnus Water Purification Corp. (CYCN), and GBS Inc. (GBS) vying for market share. The industry is characterized by high research and development costs, stringent regulatory requirements, and the need for continuous innovation. Predictive Oncology's AI-driven approach positions it to capitalize on the growing trend of personalized cancer therapies.

Who Are POAI's Key Customers?

• Pharmaceutical companies seeking to accelerate drug discovery and development.
• Hospitals and clinics looking to improve safety and efficiency in fluid management.
• Research institutions conducting preclinical oncology studies.
• Patients seeking personalized cancer treatment options.

Predictive Oncology Inc. Financial Trajectory

Predictive Oncology Inc. (POAI) reported $35K in revenue for Q1 2026, reflecting 307.1% growth compared to the prior quarter. The company recorded a net loss of $7.7M, with diluted EPS of $-0.36. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, POAI averaged $-29.13 in diluted EPS.

Company Profile

Predictive Oncology Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Pittsburgh, US. The company is led by CEO Raymond F. Vennare. POAI has traded publicly since 2010.

How Predictive Oncology Inc. Is Valued

Predictive Oncology Inc. carries a market capitalization of $3.57M, placing it in the micro-cap category. Relative to its peer group, POAI's quantitative score of 42/100 is below the peer average of 66/100.

Key Financial Metrics

Its free cash flow yield is -56.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -173.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Predictive Oncology Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -29.11 places it in the distress zone, a signal of elevated financial risk.

1/6 beatsEarnings Track Record

Predictive Oncology Inc. has missed Wall Street's EPS estimate in 5 of its last 6 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 1959.7% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Predictive Oncology Inc. revenue of about $15.4M for fiscal 2026, with EPS near $1.20.

POAI Financials

POAI Latest News

No recent news available for POAI.

POAI Analyst Consensus

POAI MoonshotScore

Predictive Oncology Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources